论文部分内容阅读
目的比较四川地区非小细胞肺癌患者外周血浆游离DNA与肺癌组织K-ras基因突变的一致性,探讨外周血K-ras检测的临床价值。方法应用突变富集液相芯片检测技术比较242例非小细胞肺癌患者的肺癌组织、外周血浆游离DNA中的K-ras基因突变检出率,观察血浆检测与组织检测的一致性。结果在本组242例非小细胞肺癌病例中,肺癌组织中检测出K-ras基因突变者共有12例患者,检出率为4.96%,外周血浆中检出10例K-ras基因突变,检出率为4.13%。外周血浆游离DNA中的K-ras基因突变检出率与肺癌组织中的检出率具有较好的一致性(Kappa值=0.81)。结论非小细胞肺癌患者外周血浆游离DNA中的K-ras可替代肺癌组织进行K-ras基因突变的筛查。
Objective To compare the consistency of K-ras gene mutation in peripheral blood plasma of patients with non-small cell lung cancer in Sichuan province and to investigate the clinical value of K-ras in peripheral blood. Methods The detection rate of K-ras mutation in lung cancer tissue and peripheral plasma free DNA of 242 patients with non-small cell lung cancer (NSCLC) was compared by the method of mutation enrichment and liquid phase microarray. The consistency of plasma and tissue detection was observed. Results In this group of 242 non-small cell lung cancer cases, 12 cases of K-ras gene mutation were detected in lung cancer tissues, the detection rate was 4.96%, 10 cases of K-ras gene mutation were detected in peripheral blood Out rate of 4.13%. The detection rate of K-ras mutation in peripheral plasma free DNA was in good agreement with the detection rate in lung cancer (Kappa value = 0.81). Conclusion K-ras in peripheral plasma free DNA of non-small cell lung cancer patients can be used to replace K-ras gene mutation screening in lung cancer.